Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TR-701 (pro-drug)
TR-701 · 1 trial · 2 indications
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
| Arm | Type | Description |
|---|---|---|
| TR-701 200 mg | EXPERIMENTAL | - |
| TR-701 300 mg | EXPERIMENTAL | - |
| TR-701 400 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TR-701 200 mg | DRUG | oral TR-701 200 mg for 5 to 7 days |
| TR-701 300 mg | DRUG | oral TR-701 300 mg for 5 to 7 days |
| TR-701 400 mg | DRUG | TR-701 400 mg for 5 to 7 days |
Inclusion Criteria: * Diagnosed with complicated skin and skin structure infection with at least 2 signs and symptoms * Suspected or confirmed infection due to a gram-positive organism Exclusion Criteria: * Complicated skin and skin structure infection due to gram-negative organisms * Complicated...
TR-701 is an investigational small molecule being studied for complicated skin and skin structure infections, including bacterial skin diseases. It is in Phase 2 clinical development and is not approved for commercial use. The development program has focused on infectious skin conditions in adult patients.
TR-701 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the clinical program evaluating TR-701 in infectious skin diseases.
TR-701 is in Phase 2 clinical development. One Phase 2 trial has been completed, and there are currently no active trials listed for the program. TR-701 is investigational and has not been approved by the FDA.
TR-701 has been evaluated in one completed Phase 2 trial, NCT00761215, titled Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections. The randomized, double-blind, controlled study enrolled 192 adults aged 18 years and older in the United States.